Other News To Note
• ElexoPharm GmbH, of Saarbruecken, Germany, said it will perform lead finding and lead optimization based on molecular modeling, design and synthesis of biological active compounds, under a EuroTransBio grant of €1.5 million (US$1.98 million). The three-year project will allow the development of low-molecular-weight inhibitors of angiogenesis in colorectal cancer in collaboration with SomantiX BV, VU University Medical Center, Saarland University and PharmBioTec GmbH.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter